Ovid Therapeutics (OVID) had its price target raised by Wedbush from $5.00 to $7.00. They now have an "outperform" rating on the stock.
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding [Seeking Alpha]
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Here's Why Ovid Therapeutics Stock Popped Higher Today [Yahoo! Finance]
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]